Share on LinkedInShare on LinkedIn

ARTICLE · 10 JULY 2026

Proprietary Data And Specialist AI: The Evolving Market In Life Sciences Transactions

Molecules have long been the primary asset in life sciences. Companies develop therapeutics, protect them with patents, and license or sell them. With the rise of artificial intelligence (AI), the data generated...

United StatesIntellectual Property

Molecules have long been the primary asset in life sciences. Companies develop therapeutics, protect them with patents, and license or sell them. With the rise of artificial intelligence (AI), the data generated in the course of researching and developing molecules has become an asset in its own right.

A market has formed around that shift. AI-native biotech companies have spent years generating the proprietary data needed to train AI models — through clinical genomics and patient sample networks, automated wet labs, and spatial biology platforms — and building the integrated platforms to do it. They now license those models as products and services to life sciences companies that are sitting on decades of their own accumulated research, which AI can analyze to identify drug candidates, predict treatment response, and map disease biology.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from